[go: up one dir, main page]

WO2023080409A1 - Composition de prévention ou de soulagement d'un trouble du sommeil, comprenant une poudre de graines de zizyphus et une poudre de fruits de rosae multiflorae - Google Patents

Composition de prévention ou de soulagement d'un trouble du sommeil, comprenant une poudre de graines de zizyphus et une poudre de fruits de rosae multiflorae Download PDF

Info

Publication number
WO2023080409A1
WO2023080409A1 PCT/KR2022/012848 KR2022012848W WO2023080409A1 WO 2023080409 A1 WO2023080409 A1 WO 2023080409A1 KR 2022012848 W KR2022012848 W KR 2022012848W WO 2023080409 A1 WO2023080409 A1 WO 2023080409A1
Authority
WO
WIPO (PCT)
Prior art keywords
powder
sleep
composition
preventing
sanzoin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2022/012848
Other languages
English (en)
Korean (ko)
Inventor
정욱
손성오
김미성
김민식
조운희
지휘원
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATUREPUREKOREA Co Ltd
Original Assignee
NATUREPUREKOREA Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATUREPUREKOREA Co Ltd filed Critical NATUREPUREKOREA Co Ltd
Publication of WO2023080409A1 publication Critical patent/WO2023080409A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725—Ziziphus, e.g. jujube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Definitions

  • the present invention relates to a composition for preventing or improving sleep disorders, and specifically relates to a composition for preventing or improving sleep disorders including sanzoin powder and youngsil powder.
  • Sleep is the most essential and important physiological phenomenon in maintaining health, and the ability to recognize and respond to the external environment is characterized by an increased reaction threshold compared to vigilance, and it is a reversible function of a normal organism. , defined as repetitive, regular, stationary or immobile. Sleep is not just a rest, but an important factor for physical recovery and mental health. It performs functions such as restoring the homeostasis of the central nervous system, regulating body temperature and energy, and organizing memory. Quality sleep improves the quality of life. It is known to help prevent various diseases.
  • Sleep disorders increase the prevalence of psychological diseases, brain diseases, vascular diseases, metabolic diseases, etc., and can also affect mortality. Treatment is generally using a lot of alternative medical therapies such as drug sleep inducers, tranquilizers, meditation, acupuncture, and massage, but it is known that immediate drug treatment can cause various side effects. Quality sleep is an indispensable element for a healthy life, and about 30% of adults have insomnia due to various causes such as work stress, irregular lifestyle, and abuse of alcohol and drugs, and about 10% or more are directly affected by insomnia. It is known to cause sleep disorders.
  • Zolpidem (a non-benzodiazepine drug) is the first prescribed drug for insomnia. Secondary prescribed drugs are benzodiazepines, which act on GABA receptors to produce therapeutic effects. However, the above drugs have various side effects such as amnesia, cognitive decline and daytime sleepiness. Due to drug dependence and abuse, benzodiazepines are not recommended for long-term intake of more than 4 weeks for insomnia prescription. Zolpidem-type drugs may be effective for insomnia, but are less effective for maintaining quality sleep. In addition, when taken for a long time, there is a problem in that side effects similar to those of benzodiazepines appear.
  • Patent Document 1 Patent Publication 10-2019-0133552
  • Non-Patent Document 1 JSchwartz, J. R., & Roth, T. (2008). Neurophysiology of sleep and wakefulness: basic science and clinical implications. Current neuropharmacology, 6(4), 367-378.
  • Non-Patent Document 2 Zammit, G. (2009). Comparative tolerability of newer agents for insomnia. Drug Safety, 32(9), 735-748.
  • the present invention is to provide a composition excellent in preventing or improving sleep disorders while having low side effects compared to synthetic drugs.
  • the present invention provides a composition for preventing or improving sleep disorders comprising sanzoin powder and/or youngsil powder.
  • Sanzoin is also called Zizyphus Seed and Zizyphi Semen, and its origin is Sanjo ( ⁇ ) Zizyphus jujuba Miller var. It refers to the ripe seed of spinosa Hu ex HF Chou ( Rhamnaceae ), and the seed coat is relatively flexible and encloses gray angiosperms and light yellow cotyledons. It has a mild oily odor and is known for its bland taste.
  • Youngsil ( ⁇ ) is also called Rosae Multiflorae Fructus, Youngsilja ( ⁇ ), and its origin is the fruit of the rose flower Rosa multiflora Thunberg ( Rosaceae ). It is known to have a sour smell and a slightly sweet taste.
  • the composition in the present invention includes sanzoin powder and / or youngsil powder, and when both sanzoin powder and youngsil powder are included, the weight ratio of sanzoin powder: youngsil powder may be 1: 1 to 2: 3. Outside the above range, the effect of preventing or improving sleep disorders may be halved.
  • the powder may be powdered after roasting raw materials of sanzoin and youngsil at 140 to 160 ° C. for 10 to 20 minutes, or powdered after hot water extraction and drying.
  • microorganisms When the roasting treatment is carried out at a temperature and time less than the above range, microorganisms may not be killed, and when the roasting treatment is performed in excess of the above temperature and time, the indicator component included in the sanzoin or youngsil may be destroyed.
  • the “sleep disorder” refers to all diseases related to sleep, and refers to symptoms of sleep disturbance due to various factors.
  • the sleep disorder include insomnia, sleep disorder, middle awakening, early awakening, insomnia, nightmare, sleepwalking, narcolepsy, abnormal behavior during sleep, hypersomnia, sleep seizure, breathing related sleep disorder, apnea, day It may be any one or more selected from the group consisting of circadian rhythm sleep disorders, parasomnia, restless legs syndrome, and periodic limb movement syndrome, but is not limited thereto.
  • composition for preventing or improving sleep disorders in the present invention may be provided as a pharmaceutical composition or a food composition.
  • the pharmaceutical composition of the present invention may additionally contain a pharmaceutically acceptable carrier and diluent.
  • the pharmaceutically acceptable carrier includes excipients such as starch, sugar, and mannitol, fillers and extenders such as calcium phosphate, cellulose derivatives such as carboxymethylcellulose and hydroxypropylcellulose, gelatin, alginates, and polyvinyl pyrrolidone. binders such as talc, calcium stearate, lubricants such as hydrogenated castor oil and polyethylene glycol, disintegrants such as povidone, crospovidone, surfactants such as polysorbates, cetyl alcohol, and glycerol.
  • the pharmaceutically acceptable diluent may be biologically and physiologically friendly to the subject. Examples of diluents include, but are not limited to, saline, aqueous buffers, solvents and/or dispersion media.
  • the pharmaceutical composition of the present invention may be formulated into an injectable formulation such as an aqueous solution, suspension, or emulsion, pill, capsule, granule, or tablet by additionally adding a dispersing agent, a surfactant, a binder, and a lubricant for administration.
  • injectable formulation such as an aqueous solution, suspension, or emulsion, pill, capsule, granule, or tablet
  • a dispersing agent such as an aqueous solution, suspension, or emulsion, pill, capsule, granule, or tablet
  • a dispersing agent such as an aqueous solution, suspension, or emulsion, pill, capsule, granule, or tablet
  • a dispersing agent such as an aqueous solution, suspension, or emulsion, pill, capsule, granule, or tablet
  • a dispersing agent such as an aqueous solution, suspension, or emulsion, pill, capsule, granule, or tablet
  • the pharmaceutical composition of the present invention can be administered orally or parenterally, for example, intravenously, subcutaneously, intraperitoneally or topically, depending on the method desired, and is preferably administered orally.
  • the dosage of the pharmaceutical composition of the present invention varies depending on the subject's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of the disease, but is not limited thereto.
  • the food composition of the present invention can be used as a health functional food.
  • health functional food refers to food manufactured and processed using raw materials or ingredients having useful functionalities for the human body in accordance with the Health Functional Food Act, and “functional” refers to food that is not related to the structure and function of the human body. It refers to intake for the purpose of obtaining useful effects for health purposes such as regulating nutrients or physiological functions.
  • the food composition of the present invention may include conventional food additives, and the suitability as the "food additive" is determined according to the general rules of the food additive code approved by the Ministry of Food and Drug Safety and general test methods, etc., unless otherwise specified. It is judged according to the specifications and standards for the item.
  • Items listed in the "Food Additive Code” include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as dark pigment, licorice extract, crystalline cellulose, goyang pigment, guar gum, Mixed preparations such as sodium L-glutamate preparation, noodle-added alkali preparation, preservative preparation, and tar color preparation may be mentioned.
  • chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid
  • natural additives such as dark pigment, licorice extract, crystalline cellulose, goyang pigment, guar gum
  • Mixed preparations such as sodium L-glutamate preparation, noodle-added alkali preparation, preservative preparation, and tar color preparation may be mentioned.
  • the food composition of the present invention can be prepared and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc., which can be conventionally prepared in the art.
  • prevention refers to all activities that inhibit or delay sleep disorders by administering the composition according to the present invention.
  • improvement refers to all actions that improve the bad condition of sleep disorder by administering or ingesting the composition of the present invention to a subject.
  • the present invention relates to a composition for preventing or improving sleep disorders, including sanzoin powder and Yeongsil powder, which is excellent in sleep induction and sleep maintenance effects, as well as in preventing and improving sleep disorders with low side effects compared to synthetic drugs.
  • a food composition and a food composition can be provided.
  • Figure 2 shows a sleep induction experiment method in the present invention.
  • Figure 3 shows the sleep induction and sleep maintenance animal test process in the present invention.
  • Figure 4 shows the results of the sleep inducing effect of the present invention.
  • Example 1 includes the sanzoin powder: Yeongsil powder in a weight ratio of 1: 1 using the sanzoin powder and Yeongsil powder of Preparation Example 2, and Example 2 was prepared by including sanzoin powder: Yeongsil powder in a weight ratio of 2:3.
  • the control group was treated with distilled water (10), and the negative control group was treated with maltodextrin (10).
  • the powder mixing ratio for each material was indicated in the ratio of 10 in total.
  • Experimental group 1 (Sanjoin powder; 5: Yeongsil powder; 5), experimental group 2 (Youngsil powder; 6: maltodextrin; 4), experimental group 3 (Sanjoin powder; 4: Yeongsil powder; 6), experimental group 4 (Sanjoin powder; 4: Maltodextrin; 6), positive control group 1 (Ecklonia cava extract; 10), and positive control group 2 (fermented rice bran extract; 10).
  • Balb/c 6-week-old (female) rats were selected and stabilized for 1 week, and then proceeded according to the purpose of the test. Breeding conditions are an environment where factors that can affect sleep are excluded, that is, a 12-hour light/dark cycle, noise (40 dB or less), lighting (200 ⁇ 300 LUX 12 h/1 day), constant temperature (22 ⁇ 3°C), Conditions such as humidity (55 ⁇ 15%) were maintained. Sleep disorder induction was confirmed by administration of caffeine 1 mg/kg, light stimulation (maintained at least 300 LUX), sound stimulation, and electrical stimulation (Mouse, 1 mA, 0.3 sec). This experiment was conducted by grouping 8 to 10 animals per experimental group, and the experimental animals had natural access to food and water, and sufficient food and water were provided before the start of the experiment.
  • Pentobarbital-induced sleep model is widely used as an experimental method to confirm the effect of sleep.
  • Pentobarbital is a barbiturate-type sedative hypnotic agent, and is known to induce sedation and sleep by enhancing GABA neurotransmission and prolonging the opening period of Cl ion channels, and exhibiting a sleep effect that maintains sleep (Fig. 2).
  • mice Using 8 to 10 mice per group, the animals were fasted for 24 hours before the experiment, and the experiment was conducted within a certain time between 1:00 pm and 6:00 pm. All samples were administered orally 45 minutes before administration of pentobarbital, and pentobarbital was intraperitoneally injected at a sleep inducing threshold concentration of 50 mg/kg. After pentobarbital treatment, each object is moved to an independent space to measure sleep latency and sleep duration. Sleep induction was evaluated by setting the elapsed time until the righting reflex was lost after intraperitoneal injection of pentobarbital, and the sleep duration was set to the time until the righting reflex was restored (FIG. 3 ).
  • the sleep induction effect was observed in experimental group 1 (Sanjoin powder; 5: Youngsil powder; 5), experimental group 3 (Sanjoin powder; 4: Youngsil powder; 6), experimental group 4 (Sanjoin powder; 4), and positive control group 2 (fermented rice bran extract; 10 ), and the sleep maintenance effect was observed in experimental group 1 (Sanjoin powder; 5: Yeongsil powder; 5), experimental group 3 (Sanjoin powder; 4: Yeongsil powder; 6), experimental group 4 (Sanjoin powder; 4), and positive control group 2 ( Rice bran fermented extract; 10).

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition de prévention ou de soulagement d'un trouble du sommeil, comprenant une poudre de graines de zizyphus et une poudre de fruits de rosae multiflorae, et peut fournir une composition présentant une excellente induction du sommeil et d'excellents effets de maintien du sommeil, ainsi que d'excellents effets de prévention et de soulagement d'un trouble du sommeil ayant de faibles effets secondaires comparée à des médicaments de synthèse.
PCT/KR2022/012848 2021-11-02 2022-08-29 Composition de prévention ou de soulagement d'un trouble du sommeil, comprenant une poudre de graines de zizyphus et une poudre de fruits de rosae multiflorae Ceased WO2023080409A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020210148977A KR102388769B1 (ko) 2021-11-02 2021-11-02 산조인 분말 및 영실 분말을 포함하는 수면 장애의 예방 또는 개선용 조성물
KR10-2021-0148977 2021-11-02

Publications (1)

Publication Number Publication Date
WO2023080409A1 true WO2023080409A1 (fr) 2023-05-11

Family

ID=81437557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/012848 Ceased WO2023080409A1 (fr) 2021-11-02 2022-08-29 Composition de prévention ou de soulagement d'un trouble du sommeil, comprenant une poudre de graines de zizyphus et une poudre de fruits de rosae multiflorae

Country Status (2)

Country Link
KR (1) KR102388769B1 (fr)
WO (1) WO2023080409A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102388769B1 (ko) * 2021-11-02 2022-04-21 네이처퓨어코리아 주식회사 산조인 분말 및 영실 분말을 포함하는 수면 장애의 예방 또는 개선용 조성물
KR102869415B1 (ko) * 2022-04-29 2025-10-14 전남대학교 산학협력단 산조인 추출물을 유효성분으로 포함하는 수면 장애 예방 또는 개선용 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100947353B1 (ko) * 2009-09-11 2010-03-15 김영식 수면장애 개선과 쾌면을 위한 건강식품 조성물
KR20170053972A (ko) * 2015-11-09 2017-05-17 한국식품연구원 영실로부터 폴리페놀 성분을 포함하는 영실 추출물을 고수율로 수득하는 방법
KR20180108515A (ko) * 2017-03-24 2018-10-04 이항종 수면장애 개선을 위한 조성물 및 그 제조방법
KR20190133552A (ko) * 2018-05-23 2019-12-03 경희대학교 산학협력단 산조인 추출물을 포함하는 카페인으로 인한 수면장애 개선용 식품 첨가제 조성물, 및 이를 포함하는 식품 조성물
KR20210053784A (ko) * 2019-11-04 2021-05-12 한국식품연구원 영실 추출물을 유효성분으로 포함하는 우울 증상, 스트레스 또는 인지기능 장애의 개선, 예방 또는 치료용 조성물
KR102388769B1 (ko) * 2021-11-02 2022-04-21 네이처퓨어코리아 주식회사 산조인 분말 및 영실 분말을 포함하는 수면 장애의 예방 또는 개선용 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100947353B1 (ko) * 2009-09-11 2010-03-15 김영식 수면장애 개선과 쾌면을 위한 건강식품 조성물
KR20170053972A (ko) * 2015-11-09 2017-05-17 한국식품연구원 영실로부터 폴리페놀 성분을 포함하는 영실 추출물을 고수율로 수득하는 방법
KR20180108515A (ko) * 2017-03-24 2018-10-04 이항종 수면장애 개선을 위한 조성물 및 그 제조방법
KR20190133552A (ko) * 2018-05-23 2019-12-03 경희대학교 산학협력단 산조인 추출물을 포함하는 카페인으로 인한 수면장애 개선용 식품 첨가제 조성물, 및 이를 포함하는 식품 조성물
KR20210053784A (ko) * 2019-11-04 2021-05-12 한국식품연구원 영실 추출물을 유효성분으로 포함하는 우울 증상, 스트레스 또는 인지기능 장애의 개선, 예방 또는 치료용 조성물
KR102388769B1 (ko) * 2021-11-02 2022-04-21 네이처퓨어코리아 주식회사 산조인 분말 및 영실 분말을 포함하는 수면 장애의 예방 또는 개선용 조성물

Also Published As

Publication number Publication date
KR102388769B1 (ko) 2022-04-21

Similar Documents

Publication Publication Date Title
US7968128B2 (en) Plant extract compositions for affecting sleep
WO2023080409A1 (fr) Composition de prévention ou de soulagement d'un trouble du sommeil, comprenant une poudre de graines de zizyphus et une poudre de fruits de rosae multiflorae
RU2672876C2 (ru) Комбинация экстракта корня валерианы и лавандового масла для применения в лечении нарушений сна
WO2025148420A1 (fr) Composition de médecine chinoise traditionnelle pour la prévention et le traitement de la sarcopénie, son procédé de préparation et son utilisation
US20170165232A1 (en) Three-phase controlled-release tablet comprising melatonin and process of preparation
US10350230B2 (en) Use of albiflorin or pharmaceutically acceptable salt for prevention and/or treatment of irritable bowel syndrome
AU2021260664B2 (en) Sleep-improving pharmaceutical composition containing rare ginsenosides Rg6 and F4
KR101256210B1 (ko) 불안 치료용 약학적 조성물
US20230125425A1 (en) Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof
JPH09227394A (ja) 経口投与用組成物
CN110215510A (zh) 聚普瑞锌在制备治疗或减轻放化疗所致消化道损伤药物中的应用
CN112641788A (zh) 5-甲基四氢叶酸组合物用于改善睡眠的应用
CN117530944A (zh) 衣康酸四辛酯在制备防治放射性肠损伤药物中的应用
CN105596312B (zh) 一种磷酸二甲啡烷胶囊组合物及其制备方法
CN104224819B (zh) 一种柚皮苷与盐酸左西替利嗪药物组合物及其制剂
WO2022097764A1 (fr) Composition pharmaceutique comprenant de la prégabaline et de la tianeptine pour traiter une douleur neuropathique
AU2018101247A4 (en) Application of persimmon leaf extract in the preparation of medicines for the treatment of primary insomnia
TW202045195A (zh) 含有卡琪花蒂瑪萃取物之組成物在緩解憂鬱症相關症狀之用途
WO2019225847A1 (fr) Composition anti-obésité ou de réduction de graisse corporelle comprenant un extrait de haricot navy et un extrait de pleurotus eryngii
KR102226052B1 (ko) 항스트레스, 항우울 및 항불안 효과를 갖는, 테아닌과 벌화분 배합물
EP3980042B1 (fr) Composition comprenant des extraits d'eucommia ulmoides, de crocus sativus et/ou de magnolia officinalis et utilisation correspondante dans le traitement de troubles du sommeil
KR20110008773A (ko) 독소필린 함유 서방출형 미세정제 및 이의 제조방법
CN108210871A (zh) 一种治疗疼痛的桂椒姜组合物
WO2025216541A1 (fr) Composition pour l'amélioration du sommeil comprenant un complexe d'extrait naturel, et son utilisation
WO2024096445A1 (fr) Composition pour améliorer, prévenir ou traiter des maladies liées au stress et à la dépression, comprenant du talampanel

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22890145

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22890145

Country of ref document: EP

Kind code of ref document: A1